BACKGROUND: MUC13 is overexpressed and aberrantly localized in colon cancer tissue; however, the specific functions and regulation of MUC13 expression are unknown. METHODS: Stable cell lines with either overexpressed or suppressed MUC13 levels were analyzed to determine cell growth, colony formation, cell migration, and cell invasion assays. The molecular mechanisms involved in MUC13 regulation were elucidated via chromatin immunoprecipitation (ChIP) and analysis of interleukin 6 (IL6) treatments. Colon cancer tissues were analyzed by immunohistochemistry (IHC) for the protein levels of MUC13 and P-STAT5 in colon cancer cells. RESULTS: Overexpression of MUC13 increased cell growth, colony formation, cell migration, and invasion. In concordance, MUC13 silencing decreased these tumorigenic features. Overexpression of MUC13 also modulated various cancer-associated proteins, including telomerase reverse transcriptase, sonic hedgehog, B cell lymphoma murine like site 1, and GATA like transcription factor 1. Additionally, MUC13-overexpressing cells showed increased HER2 and P-ERK expression. ChIP analysis revealed binding of STAT5 to the predicted MUC13 promoter. IL6 treatment of colon cancer cells increased the expression of MUC13 via activation of the JAK2/STAT5 signaling pathway. Suppression of JAK2 and STAT5 signaling by chemical inhibitors abolished IL6-induced MUC13 expression. IHC analysis showed increased expression of both P-STAT5 and MUC13 in colon cancer as compared to adjacent normal tissue. CONCLUSIONS: The results of this study, for the first time, suggest functional roles of MUC13 in colon cancer progression and provide information regarding the regulation of MUC13 expression via JAK2/STAT5 which may reveal promising therapeutic approaches for colon cancer treatment.
BACKGROUND:MUC13 is overexpressed and aberrantly localized in colon cancer tissue; however, the specific functions and regulation of MUC13 expression are unknown. METHODS: Stable cell lines with either overexpressed or suppressed MUC13 levels were analyzed to determine cell growth, colony formation, cell migration, and cell invasion assays. The molecular mechanisms involved in MUC13 regulation were elucidated via chromatin immunoprecipitation (ChIP) and analysis of interleukin 6 (IL6) treatments. Colon cancer tissues were analyzed by immunohistochemistry (IHC) for the protein levels of MUC13 and P-STAT5 in colon cancer cells. RESULTS: Overexpression of MUC13 increased cell growth, colony formation, cell migration, and invasion. In concordance, MUC13 silencing decreased these tumorigenic features. Overexpression of MUC13 also modulated various cancer-associated proteins, including telomerase reverse transcriptase, sonic hedgehog, B cell lymphomamurine like site 1, and GATA like transcription factor 1. Additionally, MUC13-overexpressing cells showed increased HER2 and P-ERK expression. ChIP analysis revealed binding of STAT5 to the predicted MUC13 promoter. IL6 treatment of colon cancer cells increased the expression of MUC13 via activation of the JAK2/STAT5 signaling pathway. Suppression of JAK2 and STAT5 signaling by chemical inhibitors abolished IL6-induced MUC13 expression. IHC analysis showed increased expression of both P-STAT5 and MUC13 in colon cancer as compared to adjacent normal tissue. CONCLUSIONS: The results of this study, for the first time, suggest functional roles of MUC13 in colon cancer progression and provide information regarding the regulation of MUC13 expression via JAK2/STAT5 which may reveal promising therapeutic approaches for colon cancer treatment.
Authors: Eric J Thompson; Kandavel Shanmugam; Christine L Hattrup; Kari L Kotlarczyk; Albert Gutierrez; Judy M Bradley; Pinku Mukherjee; Sandra J Gendler Journal: Mol Cancer Res Date: 2006-07 Impact factor: 5.852
Authors: Anca Oniscu; Roberta M James; Robert G Morris; Scott Bader; Roger D G Malcomson; David J Harrison Journal: J Pathol Date: 2004-08 Impact factor: 7.996
Authors: K Matsuo; M Oka; K Murase; H Soda; H Isomoto; F Takeshima; Y Mizuta; I Murata; S Kohno Journal: J Int Med Res Date: 2003 Mar-Apr Impact factor: 1.671
Authors: Y H Sheng; Y He; S Z Hasnain; R Wang; H Tong; D T Clarke; R Lourie; I Oancea; K Y Wong; J W Lumley; T H Florin; P Sutton; J D Hooper; N A McMillan; M A McGuckin Journal: Oncogene Date: 2016-07-11 Impact factor: 9.867
Authors: Gregory M LaMonte; Pamela Orjuela-Sanchez; Jaeson Calla; Lawrence T Wang; Shangzhong Li; Justine Swann; Annie N Cowell; Bing Yu Zou; Alyaa M Abdel-Haleem Mohamed; Zaira Hellen Villa Galarce; Marta Moreno; Carlos Tong Rios; Joseph M Vinetz; Nathan Lewis; Elizabeth A Winzeler Journal: Nat Commun Date: 2019-01-30 Impact factor: 14.919